These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

455 related items for PubMed ID: 15758796

  • 1. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials.
    Nijman RJ, Borgstein NG, Ellsworth P, Djurhuus JC.
    J Urol; 2005 Apr; 173(4):1334-9. PubMed ID: 15758796
    [Abstract] [Full Text] [Related]

  • 2. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
    Khullar V, Hill S, Laval KU, Schiøtz HA, Jonas U, Versi E.
    Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
    [Abstract] [Full Text] [Related]

  • 3. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity.
    Millard R, Tuttle J, Moore K, Susset J, Clarke B, Dwyer P, Davis BE.
    J Urol; 1999 May; 161(5):1551-5. PubMed ID: 10210394
    [Abstract] [Full Text] [Related]

  • 4. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
    Robinson D, Cardozo L, Terpstra G, Bolodeoku J, Tamsulosin Study Group.
    BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
    [Abstract] [Full Text] [Related]

  • 5. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J.
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [Abstract] [Full Text] [Related]

  • 6. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
    Rovner ES, Rackley R, Nitti VW, Wang JT, Guan Z, 037 Study Group.
    Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
    Malone-Lee JG, Al-Buheissi S.
    BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
    [Abstract] [Full Text] [Related]

  • 9. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial.
    Malone-Lee J, Shaffu B, Anand C, Powell C.
    J Urol; 2001 May; 165(5):1452-6. PubMed ID: 11342895
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
    Roehrborn CG, Abrams P, Rovner ES, Kaplan SA, Herschorn S, Guan Z.
    BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
    [Abstract] [Full Text] [Related]

  • 11. Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study.
    Nijman RJ, Borgstein NG, Ellsworth P, Siggaard C.
    Eur Urol; 2007 Nov; 52(5):1511-6. PubMed ID: 17574729
    [Abstract] [Full Text] [Related]

  • 12. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder.
    Frenkl TL, Zhu H, Reiss T, Seltzer O, Rosenberg E, Green S.
    J Urol; 2010 Aug; 184(2):616-22. PubMed ID: 20639026
    [Abstract] [Full Text] [Related]

  • 13. Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity.
    Reddy PP, Borgstein NG, Nijman RJ, Ellsworth PI.
    J Pediatr Urol; 2008 Dec; 4(6):428-33. PubMed ID: 19013412
    [Abstract] [Full Text] [Related]

  • 14. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
    Abrams P, Kaplan S, De Koning Gans HJ, Millard R.
    J Urol; 2006 Mar; 175(3 Pt 1):999-1004; discussion 1004. PubMed ID: 16469601
    [Abstract] [Full Text] [Related]

  • 15. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR, Van Kerrebroeck PE, Jünemann KP, Wang JT, Brodsky M.
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [Abstract] [Full Text] [Related]

  • 16. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder.
    Kelleher CJ, Reese PR, Pleil AM, Okano GJ.
    Am J Manag Care; 2002 Dec; 8(19 Suppl):S608-15. PubMed ID: 12516955
    [Abstract] [Full Text] [Related]

  • 17. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
    Rovner ES, Kreder K, Sussman DO, Kaplan SA, Carlsson M, Bavendam T, Guan Z.
    J Urol; 2008 Sep; 180(3):1034-41. PubMed ID: 18639297
    [Abstract] [Full Text] [Related]

  • 18. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia.
    Kaplan SA, Roehrborn CG, Dmochowski R, Rovner ES, Wang JT, Guan Z.
    Urology; 2006 Aug; 68(2):328-32. PubMed ID: 16904446
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia.
    Nitti VW, Dmochowski R, Appell RA, Wang JT, Bavendam T, Guan Z, 037 Study Group.
    BJU Int; 2006 Jun; 97(6):1262-6. PubMed ID: 16686723
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB, Zinner N, Whitmore K, Kobashi K, Snyder JA, Siami P, Karram M, Laramée C, Capo' JP, Seifeldin R, Forero-Schwanhaeuser S, Nandy I.
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.